Heteroaryl Compounds Covalently Binding FGFR4 Kinase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively targeting protein kinase-mediated diseases, such as cancer, autoimmune diseases, and neurological disorders, due to limitations in inhibiting protein kinases.
Innovation Solution
Development of irreversible inhibitors, specifically compounds of formula I, which are designed to covalently bind to protein kinases like FGFR4, providing prolonged inhibition and modulating signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to target protein kinase-mediated diseases, then treatment is provided, but the inhibition of protein kinases is insufficient and ineffective
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of kinase inhibitors to include covalent bonding capabilities. The compounds of formula I feature specific molecular parameters (reactive groups, spatial configuration) that enable covalent attachment to cysteine residues in protein kinases, fundamentally changing the binding mechanism from reversible to irreversible inhibition, thereby achieving reliable and effective inhibition across various kinase-mediated diseases
2Duration of action of moving object
If reversible inhibitors are used, then protein kinases are inhibited, but the duration of action is insufficient
Solution Approach 1:
The patent implements preliminary action through the design of covalent bonding moieties in the inhibitor molecules that form permanent bonds with target kinases before drug elimination occurs. The compounds of formula I are structured to establish irreversible covalent attachments to cysteine residues, ensuring that inhibition persists beyond the drug's pharmacokinetic half-life, thereby achieving prolonged duration of action and sustained therapeutic effect
3Duration of action of moving object
If covalent binding compounds are developed, then prolonged inhibition is achieved, but the complexity of compound design increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a pharmacophore region that provides kinase selectivity and binding affinity, and a separate covalent bonding moiety (such as acrylamide or vinyl sulfone groups) that enables irreversible attachment. This modular segmentation allows the complex function of covalent inhibition to be achieved through composed structural elements rather than monolithic complex molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit protein kinases, offering potential therapeutic benefits for various diseases by modulating signaling pathways and providing prolonged duration of action against FGFR4 signaling.
Implementation Method 1
Development of irreversible inhibitors, specifically compounds of formula I, which are designed to covalently bind to protein kinases like FGFR4
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.